Navigation Links
Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Date:9/4/2008

Data Announcements Remain on Schedule with Two Abstracts Accepted for

Presentation, and Large Clinical Data Release in November 2008

BRIDGEWATER, N.J., Sept. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced the appointment of Peter L. Garrambone, Jr. to the Company's board of directors.

Peter Garrambone's career includes more than 50 pharmaceutical transactions executed during his 24-year tenure at Pfizer, where he was a senior vice president of Corporate Strategic Planning. At Pfizer, Mr. Garrambone led the company's corporate business development and strategic planning efforts. Most recently, Mr. Garrambone was senior vice president of Business Development for Reliant Pharmaceuticals, which was sold to GlaxoSmithKline for $1.65 billion in the fall of 2007.

"We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November of this year," said David Scheer, Chairman and Co-Founder of Aegerion.

In furtherance of its strategic plan, the Company announced that it had secured additional funding from investors to support ongoing and future clinical trials. The Company will be presenting an abstract at both the American Association for the Study of Liver Disease and American Heart Association Meetings in the fourth quarter of 2008.

Aegerion anticipates receiving the results of three Phase II trials on AEGR 733 before the end of 2008. These trials, comprised of more than 460 patients, are designed to explore the efficacy, safety and tolerability of AEGR 733, Aegerion's lead compound. A Phase III study of AEGR 733 in the orphan population of homozygous familial hypercholesterolemic patients is currently underway.

In addition, Aegerion announced the transition of Jerry Wisler, Co- Founder, CEO and Director of Aegerion, who has left the Company to pursue personal interests.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's primary focus is on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase III and Phase II testing.


'/>"/>
SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  Venice,s newest laser clinic, ... first of its kind in the area and ... advanced laser treatment. The physician-owned and operated laser ... Suncoast by storm with its revitalizing skin care ... multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... Feb. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... previously announced underwritten secondary offering of 11,027,558 shares of ... of affiliates of Blackstone and Goldman Sachs.  The shares ... price of $96.45 per share. The selling stockholders will ... Zimmer Biomet nor any of its directors, officers or ...
(Date:2/5/2016)... , February 5, 2016 ... Today, VoicePower Ltd - The Speech Recognition People, announced their ... deployed to improve patient care, reduce turnaround times and to save ... CCG ,- VoicePower client since 2013 Challenge: --> ... Challenge: --> - Six doctors ,- Wirral CCG ,- ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... After years as ... Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of ... He successfully completed his first three-year term as chief and began a second three-year ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced ... and donate to Give To Cure’s campaign that is crowdfunding clinical trials to help ... and share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... announced the election of Patrick McDermott as Chairman of the National Board of Directors. ... Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA President ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, ... it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the ... oral health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , ...
Breaking Medicine News(10 mins):